C4 Therapeutics Inc (CCCC) Stock Price, Quote & News

Company Profile

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 clinical trials targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting BR...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 231 0700

Website: www.c4therapeutics.com

Address:

490 Arsenal Way, Suite120, Watertown, United States

zawojak Aug. 18 at 6:54 PM

$CCCC Well done Longs 👏✔️👍 $3

0 · Reply

jackedtothetitss Aug. 18 at 6:44 PM

$CCCC 🚀🚀🚀

0 · Reply

Andysss Aug. 18 at 6:07 PM

$CCCC Volume above average but still relatively light??? A close above $2.86 could open room toward $3.20+ But wold like to see more volume

0 · Reply

stellar Aug. 18 at 6:05 PM

$CCCC she is ready.

0 · Reply

stellar Aug. 18 at 6:04 PM

$SNGX ready. Just like $CCCC.

0 · Reply

DARKP00L Aug. 18 at 5:32 PM

$CCCC high mentions of this stock today! Potential for volatility!

0 · Reply

LabPsycho Aug. 18 at 5:07 PM

$CCCC I've said it before and will post it again...$CCCC should explore a partnership with $NVDA for doing molecular dynamic simulations like I have done (see YouTube video link below if you are interested the methodology). It would give them a huge drug discovery and development advantage over the competition, IMO. https://www.youtube.com/watch?v=NZCPeihFmts&t=4s

1 · Reply

LabPsycho Aug. 18 at 3:37 PM

$CCCC To add to my post below - if you are interested in comparing $CCCC to $TNGX check the chart of TNGX...when TNGX was $1.26 similar shares, market cap and cash to CCCC...then the large swings started up and down sometimes almost 10% a day. And the volume increases vs normal. TNGX from ~ $1.2 to almost $7 in a couple of months...seemingly triggered by starting a phase 1. I see many similarities between CCCC and TNGX. Good luck.

0 · Reply

LabPsycho Aug. 18 at 2:57 PM

$CCCC IMO, The move of CCCC the past several weeks is reminiscent of the recent pattern of TNGX 500% gain from April to July , including the large moves and retraces. Just a thought...

1 · Reply

LabPsycho Aug. 18 at 2:37 PM

$CCCC Looking like going to float up past previous high of $2.92 in a week or so. In addition as I have been posting for a while, IMO, it seems the daily trade volume for CCCC considering the outstanding # of shares is about 2X vs other comparable sized biotechs. It also moves more than expected (on no news) than other comps.) Considering this I think 2.92 is more likely than 2.22 near term. Good luck

0 · Reply

C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Jun 16, 2025, 1:50 PM EDT - 2 months ago

C4 Therapeutics: An Entry Point If There's Ever Going To Be One

May 7, 2025, 7:00 AM EDT - 3 months ago

C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

Feb 27, 2025, 7:00 AM EST - 6 months ago

C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Feb 24, 2025, 7:00 AM EST - 6 months ago

C4 Therapeutics to Participate in Upcoming March Investor Conferences

Dec 8, 2024, 12:30 PM EST - 9 months ago

C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader

Nov 20, 2024, 7:00 AM EST - 9 months ago

C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors

Oct 28, 2024, 4:01 PM EDT - 10 months ago

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Oct 15, 2024, 4:01 PM EDT - 10 months ago

C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.

Oct 9, 2024, 7:00 AM EDT - 11 months ago

C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit

Sep 13, 2024, 10:00 AM EDT - 1 year ago

C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

Sep 8, 2024, 6:05 PM EDT - 1 year ago

C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024

Sep 3, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors

Aug 29, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics to Participate in Upcoming September Investor Conferences

Aug 1, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Jul 16, 2024, 4:01 PM EDT - 1 year ago

C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024

Jul 8, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day

Jun 10, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors

May 8, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Apr 9, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum

Apr 8, 2024, 8:00 AM EDT - 1 year ago

C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024

Mar 5, 2024, 4:30 PM EST - 1 year ago

C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024

Mar 4, 2024, 7:00 AM EST - 1 year ago

C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins

Feb 22, 2024, 7:00 AM EST - 1 year ago

C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Jan 9, 2024, 4:01 PM EST - 1 year ago

C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines

Jan 4, 2024, 4:01 PM EST - 1 year ago

C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals

Jan 4, 2024, 7:00 AM EST - 1 year ago

C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

$C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma$

Dec 12, 2023, 4:01 PM EST - 1 year ago

C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma

Dec 12, 2023, 7:00 AM EST - 1 year ago

C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs)

$C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma$

Nov 28, 2023, 7:00 AM EST - 1 year ago

C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma

Nov 20, 2023, 7:00 AM EST - 1 year ago

C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment

Nov 1, 2023, 7:00 AM EDT - 1 year ago

C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Oct 11, 2023, 7:00 AM EDT - 2 years ago

C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC™ Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, and CFT7455, an Orally Bioavailable MonoDAC™ Degrader in Development for Multiple Myelom

Sep 5, 2023, 4:01 PM EDT - 2 years ago

C4 Therapeutics Announces Chief Financial Officer Succession

Aug 8, 2023, 7:00 AM EDT - 2 years ago

C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Jul 15, 2023, 1:58 AM EDT - 2 years ago

C4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 5, 2023, 7:00 AM EDT - 2 years ago

C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT8919, an Orally Bioavailable BiDAC™ Degrader Targeting EGFR L858R for Non-Small Cell Lung Cancer

Jun 20, 2023, 7:00 AM EDT - 2 years ago

C4 Therapeutics Appoints Leonard Reyno, M.D., as Chief Medical Officer

May 30, 2023, 7:00 AM EDT - 2 years ago

C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC™ Degrader of EGFR L858R for NSCLC

May 4, 2023, 7:00 AM EDT - 2 years ago

C4 Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

Apr 19, 2023, 7:00 AM EDT - 2 years ago

C4 Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days

Feb 23, 2023, 7:00 AM EST - 2 years ago

C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

Feb 8, 2023, 7:00 AM EST - 2 years ago

C4 Therapeutics to Present at Two Virtual February 2023 Conferences

Jan 30, 2023, 7:00 AM EST - 2 years ago

C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF V600 Mutant Solid Tumors

Jan 9, 2023, 7:00 AM EST - 2 years ago

C4 Therapeutics Announces 2023 Strategic Priorities to Advance Portfolio of Targeted Protein Degradation Medicines

Jan 3, 2023, 7:00 AM EST - 2 years ago

C4 Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Nov 3, 2022, 7:00 AM EDT - 3 years ago

C4 Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights

Sep 29, 2022, 7:00 AM EDT - 3 years ago

C4 Therapeutics Receives Study May Proceed Letter from U.S. FDA to Initiate Phase 1/2 Clinical Trial of CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF-V600 Mutant Solid Cancers

Sep 26, 2022, 7:00 AM EDT - 3 years ago

C4 Therapeutics to Present at Bank of America Securities Precision Oncology Conference 2022

Aug 4, 2022, 8:00 AM EDT - 3 years ago

C4 Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights

zawojak Aug. 18 at 6:54 PM

$CCCC Well done Longs 👏✔️👍 $3

0 · Reply

jackedtothetitss Aug. 18 at 6:44 PM

$CCCC 🚀🚀🚀

0 · Reply

Andysss Aug. 18 at 6:07 PM

$CCCC Volume above average but still relatively light??? A close above $2.86 could open room toward $3.20+ But wold like to see more volume

0 · Reply

stellar Aug. 18 at 6:05 PM

$CCCC she is ready.

0 · Reply

stellar Aug. 18 at 6:04 PM

$SNGX ready. Just like $CCCC.

0 · Reply

DARKP00L Aug. 18 at 5:32 PM

$CCCC high mentions of this stock today! Potential for volatility!

0 · Reply

LabPsycho Aug. 18 at 5:07 PM

1 · Reply

LabPsycho Aug. 18 at 3:37 PM

0 · Reply

LabPsycho Aug. 18 at 2:57 PM

$CCCC IMO, The move of CCCC the past several weeks is reminiscent of the recent pattern of TNGX 500% gain from April to July , including the large moves and retraces. Just a thought...

1 · Reply

LabPsycho Aug. 18 at 2:37 PM

0 · Reply

LabPsycho Aug. 18 at 2:33 PM

$CCCC @VNVRCH Good work. I have noticed the October calls inordinate volume to the seeming upside. Please do more research and share your findings and opinion here.

1 · Reply

DARKP00L Aug. 18 at 2:28 PM

$CCCC the market is buzzing about this stock. Expect possible price changes!

0 · Reply

vu_jade Aug. 18 at 2:26 PM

$CCCC yes sir ..

1 · Reply

DARKP00L Aug. 18 at 2:24 PM

$CCCC this stock is seeing a surge in interest. Market volatility might ensue!

0 · Reply

Andysss Aug. 18 at 1:32 PM

$CCCC halted?

0 · Reply

zawojak Aug. 18 at 1:07 PM

$CCCC To da mooooonnnnaaaa!!!

0 · Reply

Rikilk Aug. 18 at 8:48 AM

$CCCC Let’s break $3 until Friday

0 · Reply

VNVRCH Aug. 17 at 8:37 PM

$CCCC Mapping of Total Gamma. Odds are in our favor :) *Trying to find the share of Retail/Tute GEX to refine main assumption...

0 · Reply

Meyers772 Aug. 16 at 11:19 PM

$CCCC Tutes are buying big time...look at Fintel....

0 · Reply

Meyers772 Aug. 16 at 11:15 PM

$CCCC See you at five bucks soon......

0 · Reply

vu_jade Aug. 15 at 4:58 PM

$CCCC 5th C: Continuation

0 · Reply

zawojak Aug. 15 at 11:45 AM

$CCCC Data readout expected next month. I hope to wake up to $5-7 SP

1 · Reply

Market Cap	175.08M
Revenue (ttm)	35.58M
Net Income (ttm)	-105.32M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-296.01%
Debt to Equity Ratio	0.00

Volume	3,059,607
Avg Vol	1,611,252
Day's Range	N/A - N/A
Shares Out	71.17M
Stochastic %K	52%
Beta	2.97
Analysts	Strong Sell
Price Target	$12.93